Creo Medical Group PLC Exercise of Options (7363K)
December 17 2018 - 11:28AM
UK Regulatory
TIDMCREO
RNS Number : 7363K
Creo Medical Group PLC
17 December 2018
Creo Medical Group plc
("Creo" or the "Company")
Exercise of Options
Creo Medical Group plc (AIM: CREO), a medical device company
focused on the emerging field of surgical endoscopy, confirms that
it has issued, conditional on admission, 172,440 new ordinary
shares of GBP0.001 each in the capital of the Company (the "New
Shares"), pursuant to an exercise of share options by an employee
of the Company.
Application has been made to the London Stock Exchange for
admission of the New Shares to trading on AIM and dealings are
expected to commence on 21 December 2018 ("Admission").
Following Admission, Creo will have a total of 120,495,385
ordinary shares of GBP0.001 each in issue. This figure may be used
by shareholders as the denominator for the calculations by which
they will determine if they are required to notify their interest
in, or a change to their interest in Creo.
Creo Medical Group plc
Richard Rees (CFO) +44 (0)129 160 6005
Cenkos Securities +44 (0)20 7397 8900
Stephen Keys/Mark Connelly
(NOMAD)
Michael Johnson / Russell Kerr
(Sales)
Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Helen Cresswell Mob: +44 (0)7841 917 679
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and radiowave energy to surgical endoscopy. Creo
has developed CROMA, an electrosurgical platform that combines
bipolar radiofrequency for precise localised cutting and microwave
for controlled coagulation. This technology provides physicians
with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring its CROMA platform to market
through a suite of medical devices which the Company has designed,
initially for the emerging field of GI therapeutic endoscopy, an
area with high unmet needs. The CROMA platform will be developed
further for bronchoscopy and laparoscopy procedures. The Company
believes its technology can impact the landscape of surgery and
endoscopy by providing safer, less-invasive and more cost-efficient
option of treatment.
For more information about Creo Medical please see our website,
www.creomedical.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEGGGCPPUPRGQM
(END) Dow Jones Newswires
December 17, 2018 11:28 ET (16:28 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2023 to Apr 2024